4TEEN4 Pharmaceuticals GmbH
4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.
Industries
Nr. of Employees
small (1-50)
4TEEN4 Pharmaceuticals GmbH
Neuendorfstrasse 15A, 16761 Hennigsdorf, Germany
Patents
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
US-11530276-B2
View Details
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
US-11530276-B2
View DetailsProducts
Clinical-stage monoclonal antibody inhibitor of circulating DPP3 (clinical candidate)
A humanized monoclonal antibody therapeutic candidate developed to bind and inhibit circulating dipeptidyl peptidase 3 (cDPP3); shown to modulate hemodynamics and RAAS-related peptide degradation in preclinical models and progressed through Phase 1 clinical evaluation.
Clinical-stage monoclonal antibody inhibitor of circulating DPP3 (clinical candidate)
A humanized monoclonal antibody therapeutic candidate developed to bind and inhibit circulating dipeptidyl peptidase 3 (cDPP3); shown to modulate hemodynamics and RAAS-related peptide degradation in preclinical models and progressed through Phase 1 clinical evaluation.
Services
Out-licensing of a circulating protein biomarker for incorporation into diagnostic platforms to predict and monitor cardiogenic shock.
Clinical program management for a therapeutic candidate developed to inhibit a circulating protease target, including Phase 1 completion and planned Phase 1b/2a and Phase 2/3 studies with biomarker selection.
Out-licensing of a circulating protein biomarker for incorporation into diagnostic platforms to predict and monitor cardiogenic shock.
Clinical program management for a therapeutic candidate developed to inhibit a circulating protease target, including Phase 1 completion and planned Phase 1b/2a and Phase 2/3 studies with biomarker selection.
Expertise Areas
- Biomarker-driven therapeutics
- Monoclonal antibody development
- Cardiovascular critical care therapeutics
- Clinical trial management (Phase 1 to Phase 3)
Key Technologies
- Monoclonal antibody therapeutics
- Circulating protein biomarker assays
- Point-of-care immunoassay platforms (inferred)
- Preclinical animal efficacy models
News & Updates
4TEEN4 successfully completed its Phase 1 clinical trial for Procizumab, confirming a favorable safety profile and preparing for further clinical trials in circulatory failure.
Raised approximately €24 million in Series C financing to support the next clinical trials for Procizumab.
Adrien Picod received the Albert Sézary Prize from the Académie Nationale de Médecine de France for research on cDPP3 in circulatory failure, in collaboration with 4TEEN4.
First closing of Series C financing round with €14 million, welcoming Görlich GmbH & Co. 1. Biotech KG as lead investor.
Florian A. Wenzl, MD, received the European Society of Cardiology Young Investigator Award for a study identifying cDPP3 as a novel biomarker of cardiogenic shock.
Dosing of the first subject in Phase 1 study of Procizumab at Radboud University, Netherlands.
4TEEN4 successfully completed its Phase 1 clinical trial for Procizumab, confirming a favorable safety profile and preparing for further clinical trials in circulatory failure.
Raised approximately €24 million in Series C financing to support the next clinical trials for Procizumab.
Adrien Picod received the Albert Sézary Prize from the Académie Nationale de Médecine de France for research on cDPP3 in circulatory failure, in collaboration with 4TEEN4.
First closing of Series C financing round with €14 million, welcoming Görlich GmbH & Co. 1. Biotech KG as lead investor.
Florian A. Wenzl, MD, received the European Society of Cardiology Young Investigator Award for a study identifying cDPP3 as a novel biomarker of cardiogenic shock.
Dosing of the first subject in Phase 1 study of Procizumab at Radboud University, Netherlands.